Literature DB >> 30242023

Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes.

Kumardeep Chaudhary1, Olivier B Poirion1, Liangqun Lu1,2, Sijia Huang1,2, Travers Ching1,2, Lana X Garmire3,2.   

Abstract

Although driver genes in hepatocellular carcinoma (HCC) have been investigated in various previous genetic studies, prevalence of key driver genes among heterogeneous populations is unknown. Moreover, the phenotypic associations of these driver genes are poorly understood. This report aims to reveal the phenotypic impacts of a group of consensus driver genes in HCC. We used MutSigCV and OncodriveFM modules implemented in the IntOGen pipeline to identify consensus driver genes across six HCC cohorts comprising 1,494 samples in total. To access their global impacts, we used The Cancer Genome Atlas (TCGA) mutations and copy-number variations to predict the transcriptomics data, under generalized linear models. We further investigated the associations of the consensus driver genes to patient survival, age, gender, race, and risk factors. We identify 10 consensus driver genes across six HCC cohorts in total. Integrative analysis of driver mutations, copy-number variations, and transcriptomic data reveals that these consensus driver mutations and their copy-number variations are associated with a majority (62.5%) of the mRNA transcriptome but only a small fraction (8.9%) of miRNAs. Genes associated with TP53, CTNNB1, and ARID1A mutations contribute to the tripod of most densely connected pathway clusters. These driver genes are significantly associated with patients' overall survival. Some driver genes are significantly linked to HCC gender (CTNNB1, ALB, TP53, and AXIN1), race (TP53 and CDKN2A), and age (RB1) disparities. This study prioritizes a group of consensus drivers in HCC, which collectively show vast impacts on the phenotypes. These driver genes may warrant as valuable therapeutic targets of HCC. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30242023      PMCID: PMC6542354          DOI: 10.1158/1078-0432.CCR-18-0088

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection.

Authors:  Xiuming Zhang; Yanfeng Bai; Lei Xu; Buyi Zhang; Shi Feng; Liming Xu; Han Zhang; Linjie Xu; Pengfei Yang; Tianye Niu; Shusen Zheng; Jimin Liu
Journal:  Hepatol Int       Date:  2019-09-17       Impact factor: 6.047

2.  Two-stage Cox-nnet: biologically interpretable neural-network model for prognosis prediction and its application in liver cancer survival using histopathology and transcriptomic data.

Authors:  Zhucheng Zhan; Zheng Jing; Bing He; Noshad Hosseini; Maria Westerhoff; Eun-Young Choi; Lana X Garmire
Journal:  NAR Genom Bioinform       Date:  2021-03-22

3.  A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.

Authors:  Jacqueline Olender; Bi-Dar Wang; Travers Ching; Lana X Garmire; Kaitlin Garofano; Youngmi Ji; Tessa Knox; Patricia Latham; Kenneth Nguyen; Johng Rhim; Norman H Lee
Journal:  Mol Cancer Res       Date:  2019-07-02       Impact factor: 5.852

Review 4.  Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.

Authors:  Julien Calderaro; Tobias Paul Seraphin; Tom Luedde; Tracey G Simon
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 5.  Advances in genomic hepatocellular carcinoma research.

Authors:  Weitai Huang; Anders Jacobsen Skanderup; Caroline G Lee
Journal:  Gigascience       Date:  2018-11-01       Impact factor: 6.524

6.  Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.

Authors:  Marianna Alunni-Fabbroni; Kerstin Rönsch; Thomas Huber; Clemens C Cyran; Max Seidensticker; Julia Mayerle; Maciej Pech; Bristi Basu; Chris Verslype; Julia Benckert; Peter Malfertheiner; Jens Ricke
Journal:  J Transl Med       Date:  2019-10-01       Impact factor: 5.531

7.  eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA.

Authors:  Kei Mizuno; Shusuke Akamatsu; Takayuki Sumiyoshi; Jing Hao Wong; Masashi Fujita; Kazuaki Maejima; Kaoru Nakano; Atushi Ono; Hiroshi Aikata; Masaki Ueno; Shinya Hayami; Hiroki Yamaue; Kazuaki Chayama; Takahiro Inoue; Osamu Ogawa; Hidewaki Nakagawa; Akihiro Fujimoto
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

Review 8.  Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.

Authors:  Bin Chen; Lana Garmire; Diego F Calvisi; Mei-Sze Chua; Robin K Kelley; Xin Chen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-01-03       Impact factor: 46.802

Review 9.  Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma.

Authors:  Ramesh P Thylur; Sanjit K Roy; Anju Shrivastava; Thomas A LaVeist; Sharmila Shankar; Rakesh K Srivastava
Journal:  JGH Open       Date:  2020-04-15

10.  Identification of a novel gene signature for the prediction of recurrence in HCC patients by machine learning of genome-wide databases.

Authors:  Jie Shen; Liang Qi; Zhengyun Zou; Juan Du; Weiwei Kong; Lianjun Zhao; Jia Wei; Ling Lin; Min Ren; Baorui Liu
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.